Abstract
A pilot study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer has been started in Korea. Archival tumor samples were tested for HRD and PD-L1 status. Treatment arms will be allocated according to the test results. For HRD+ patients, we tested the synergistic effects of olaparib and other agents; treatment arms will randomly be allocated. (Arm 1: olaparib and cediranib; Arm 2: olaparib and durvalumab). For HRD- patients, we tested the role of biomarker-driven immunotherapy according to PD-L1 expression (Arm 3: durvalumab and chemotherapy in patients with high PD-L1 expression; Arm 4: durvalumab, tremelimumab, and chemotherapy in patients with low PD-L1 expression). Sixty-eight patients will be included from three Korean institutions within 1 year. The primary endpoint is the response rate according to RECIST 1.1 (6 months after treatment initiation). This trial has been registered with clinicaltrials.gov, and the registration number is NCT03699449.
| Original language | English |
|---|---|
| Pages (from-to) | 789-792 |
| Number of pages | 4 |
| Journal | Japanese Journal of Clinical Oncology |
| Volume | 49 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2019 Aug 1 |
Bibliographical note
Funding Information:This work was supported by HANDOK JESEOK FOUNDATION.
Funding Information:
We appreciate the contribution of investigators and study teams at the participating sites and KGOG. Yonsei University Health system, Severance Hospital Eun Ji Nam Sang Wun Kim Young Shin Chung Yong Jae Lee Kyung Hee Cho Youna Kim Sungkyunkwan University Samsung Medical Center Duk-Soo Bae Jeong Won Lee Tae-Joong Kim Yoo Young Lee Eun Hwa Choi Seoul National University Hospital Maria Lee Se Ik Kim Nara Lee Myung Hee Nam KGOG Young Sook Choi Jong Soon Kim Samsung Genome Institute Je-Gun Joung Jongsuk Chung This work was supported by the Severance Hospital Research Fund for Clinical Excellence. This work was supported by HANDOK JESEOK FOUNDATION.
Funding Information:
Jung-Yun Lee received research funding from Roche, Janssen, and AstraZeneca.
Funding Information:
This work was supported by the Severance Hospital Research Fund for Clinical Excellence.
Publisher Copyright:
© The Author(s) 2019. Published by Oxford University Press. All rights reserved.
All Science Journal Classification (ASJC) codes
- Oncology
- Radiology Nuclear Medicine and imaging
- Cancer Research
